France Follows Suit on Continent with 225G in Fatalities, Including a 225G Case with TamiFlu Resistance

France announces the presence of 225G associated with fatalities and indicates that one of the 225G strains is also TamiFlu Resistant

Less than one week after the first official announcement from Norway, western Europe has a growing coverage of confirmed and probable 225G cases.  As we mentioned on the 23rd of November, many countries will now open their databases concerning this RBD change.  Those databases will confirm not that 225G is spreading, but that 225G was already widely dispersed and is spreading faster than we had previously been led to believe.

A glaring signal is apparent concerning the public's right to information that may protect their health.  Release of important policy-making and family protection information has been blocked as the taxpayer-funded research centers and public health officials continue to withhold even the sparse data from the limited surveillance that has been conducted.

The leading world health agency reports a rise in TamiFlu Resistant sequences to 75 cases, geographically dispersed, while continuing to read the script of "spontaneous mutation, not transmitting" over the increasing set of clustered cases.  All TamiFlu Resistant cases from PF11 have had the same Single Nucleotide Polymorphism coding for 275Y in the Neuraminidase and this French case is expected to follow suit.  Not random and not spontaneous.  We have tracked the details of the 13 available public anti-viral resistant sequences for variation.

225G is now being reported widely as countries increase transparency concerning the antigenic diversity and transmissibility of strains carrying this important Receptor Binding Domain change that has, on lab examination of the 1918 strains, conferred dual receptor specificity for tissue in the upper respiratory system and the deep lung tissue.

Countries with Probable * or Confirmed 225G
This drug resistant strain with antigenic diversity in France, an international travel hub, is one Hydra head that merits deep scrutiny. 

Several questions come to mind concerning the French report considering the paired cross-segment changes on the Norway3364 sample from September, HA syn413K and NA syn407V.  At the instant that research centers are identifying cross-segment linkages, we are now presented with a second set of pairs crossing the same two segments, HA 225G and NA 275Y.

Are the French cases contemporary?  What are the clinical details?   Note also that France published one of the first 225E sequences with Paris2591 from a 23M on 2009-05-01.

225G and 225E strains are co-circulating around the world, in one French case with TamiFlu Resistance, killing hosts quickly by destroying the lungs.  Of deepest interest is the exhibition of clear vaccine escape signals if the low reactor status update of one recent Ukraine 225G, LvivN6, is validated.  Antigenic diversity, whether due to viral response to human immunity, anti-viral selection pressure or vaccine pressure, is a certainty.

ΣPF11 is now officially Hydra.

Please visit GeneWurx.com for insight into the latest published studies.